Company / Operating Cash Flow
Protalix BioTherapeutics, Inc. Operating Cash Flow History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$1.3M
FY2025
5-year range
-$26.1M / -$1.3M
FY2021-FY2025
Trend
+94.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$31M in FY2015 to -$1M in FY2025.
Based on SEC 10-K filings.
-$1M in FY2025.
Improved from -$10M to -$1M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 94.7% year-over-year.
- Lowest operating cash flow in the period was in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.3M | +94.7% |
| FY2024 | -$25.0M | -143.1% |
| FY2023 | -$10.3M | +60.6% |
| FY2022 | -$26.1M | -34.9% |
| FY2021 | -$19.4M | -150.0% |
| FY2020 | -$7.7M | +22.5% |
| FY2019 | -$10.0M | +58.8% |
| FY2017 | -$24.3M | +17.1% |
| FY2016 | -$29.3M | +4.5% |
| FY2015 | -$30.7M | -4927.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026